Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 14 | 2012 | 74 | 2.000 |
Why?
|
| Neoplasms | 15 | 2015 | 1341 | 1.050 |
Why?
|
| Vitamins | 6 | 2015 | 81 | 0.840 |
Why?
|
| Micronutrients | 4 | 2015 | 45 | 0.800 |
Why?
|
| Stress, Psychological | 6 | 2014 | 641 | 0.800 |
Why?
|
| Antioxidants | 7 | 2005 | 439 | 0.660 |
Why?
|
| Lipid Peroxidation | 7 | 1998 | 141 | 0.610 |
Why?
|
| Enzymes | 3 | 2015 | 34 | 0.600 |
Why?
|
| Dietary Supplements | 5 | 2015 | 208 | 0.580 |
Why?
|
| Malnutrition | 3 | 2015 | 44 | 0.570 |
Why?
|
| Feeding Behavior | 5 | 2015 | 461 | 0.560 |
Why?
|
| Students | 5 | 2013 | 617 | 0.530 |
Why?
|
| Models, Biological | 5 | 2015 | 711 | 0.450 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 38 | 0.440 |
Why?
|
| Stress, Physiological | 1 | 2014 | 170 | 0.400 |
Why?
|
| Energy Metabolism | 2 | 2015 | 181 | 0.370 |
Why?
|
| Diet | 3 | 2014 | 810 | 0.370 |
Why?
|
| Minerals | 3 | 2015 | 52 | 0.350 |
Why?
|
| Fish Oils | 4 | 1995 | 13 | 0.340 |
Why?
|
| Dietary Fats | 5 | 1998 | 117 | 0.340 |
Why?
|
| Breast Neoplasms | 6 | 2006 | 1679 | 0.310 |
Why?
|
| Humans | 44 | 2015 | 42163 | 0.310 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 585 | 0.280 |
Why?
|
| Fatty Acids | 3 | 2004 | 134 | 0.260 |
Why?
|
| Smoking | 1 | 2013 | 1019 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 744 | 0.240 |
Why?
|
| Blood Glucose | 3 | 2015 | 386 | 0.230 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 20 | 0.220 |
Why?
|
| Research | 1 | 2006 | 177 | 0.220 |
Why?
|
| Anti-Obesity Agents | 1 | 2004 | 11 | 0.220 |
Why?
|
| Models, Theoretical | 1 | 2006 | 230 | 0.220 |
Why?
|
| Membrane Lipids | 1 | 2004 | 29 | 0.220 |
Why?
|
| Triglycerides | 1 | 2004 | 146 | 0.210 |
Why?
|
| Self Medication | 2 | 2013 | 13 | 0.200 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 1995 | 69 | 0.200 |
Why?
|
| Adipose Tissue | 1 | 2004 | 180 | 0.200 |
Why?
|
| Cholesterol | 1 | 2004 | 230 | 0.190 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 2598 | 0.190 |
Why?
|
| Orthomolecular Therapy | 1 | 2002 | 3 | 0.190 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.190 |
Why?
|
| Puerto Rico | 7 | 2013 | 1376 | 0.180 |
Why?
|
| Obesity | 4 | 2015 | 1131 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 37 | 0.160 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 4 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2000 | 51 | 0.160 |
Why?
|
| Child Nutrition Disorders | 1 | 2000 | 10 | 0.160 |
Why?
|
| Universities | 5 | 2013 | 539 | 0.150 |
Why?
|
| Education, Medical | 1 | 2000 | 117 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2000 | 115 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 1112 | 0.150 |
Why?
|
| Animals | 13 | 2015 | 16695 | 0.150 |
Why?
|
| Socioeconomic Factors | 5 | 2013 | 1221 | 0.150 |
Why?
|
| Female | 19 | 2013 | 24018 | 0.150 |
Why?
|
| Coenzymes | 2 | 2015 | 13 | 0.140 |
Why?
|
| Neural Tube Defects | 1 | 1997 | 3 | 0.140 |
Why?
|
| Folic Acid Deficiency | 1 | 1997 | 6 | 0.140 |
Why?
|
| Income | 3 | 2013 | 160 | 0.140 |
Why?
|
| Folic Acid | 1 | 1997 | 49 | 0.140 |
Why?
|
| Male | 14 | 2015 | 22779 | 0.130 |
Why?
|
| Food | 2 | 2015 | 102 | 0.130 |
Why?
|
| Drinking Behavior | 2 | 2015 | 18 | 0.130 |
Why?
|
| Cell Membrane | 2 | 2012 | 400 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 134 | 0.120 |
Why?
|
| Adult | 10 | 2013 | 13458 | 0.120 |
Why?
|
| Adaptation, Psychological | 3 | 2013 | 410 | 0.120 |
Why?
|
| Apraxias | 1 | 2015 | 1 | 0.120 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2015 | 1 | 0.120 |
Why?
|
| Shal Potassium Channels | 1 | 2015 | 2 | 0.120 |
Why?
|
| Hazardous Substances | 1 | 2015 | 18 | 0.120 |
Why?
|
| Lipolysis | 1 | 1995 | 20 | 0.120 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 35 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 165 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2015 | 1586 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 63 | 0.110 |
Why?
|
| Adipocytes | 1 | 1995 | 58 | 0.110 |
Why?
|
| Cell Death | 3 | 2006 | 277 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 2 | 2013 | 181 | 0.110 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1998 | 9 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 1996 | 378 | 0.110 |
Why?
|
| Middle Aged | 8 | 2013 | 11819 | 0.100 |
Why?
|
| Caffeine | 1 | 2013 | 28 | 0.100 |
Why?
|
| Injections, Intravenous | 4 | 2011 | 65 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 234 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 506 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2015 | 247 | 0.100 |
Why?
|
| Beverages | 1 | 2013 | 65 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 97 | 0.100 |
Why?
|
| Fermentation | 1 | 2012 | 38 | 0.100 |
Why?
|
| Young Adult | 5 | 2013 | 4936 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2015 | 429 | 0.090 |
Why?
|
| Glycolysis | 1 | 2012 | 71 | 0.090 |
Why?
|
| Diabetic Neuropathies | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cell Division | 3 | 2002 | 314 | 0.090 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 1991 | 29 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 385 | 0.090 |
Why?
|
| Oxygen | 1 | 2012 | 217 | 0.090 |
Why?
|
| Rats | 3 | 2014 | 3701 | 0.090 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 55 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 3077 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 174 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 438 | 0.080 |
Why?
|
| Vitamin E | 1 | 1990 | 56 | 0.080 |
Why?
|
| Sepsis | 1 | 2011 | 90 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2015 | 733 | 0.080 |
Why?
|
| Weight Loss | 2 | 2015 | 138 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2012 | 633 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 516 | 0.070 |
Why?
|
| Mice | 7 | 2004 | 6490 | 0.070 |
Why?
|
| Exercise | 1 | 2013 | 674 | 0.070 |
Why?
|
| Mice, Nude | 3 | 1993 | 403 | 0.060 |
Why?
|
| Time Factors | 1 | 2010 | 1848 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 43 | 0.060 |
Why?
|
| Forecasting | 1 | 2006 | 136 | 0.060 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 21 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2005 | 144 | 0.060 |
Why?
|
| Nutritional Requirements | 2 | 2015 | 33 | 0.060 |
Why?
|
| Palliative Care | 1 | 2005 | 61 | 0.060 |
Why?
|
| Herbal Medicine | 1 | 2004 | 8 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 698 | 0.050 |
Why?
|
| Anthropometry | 1 | 2004 | 96 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2004 | 78 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2004 | 305 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 249 | 0.050 |
Why?
|
| Oxidation-Reduction | 2 | 1995 | 448 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 1993 | 129 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 290 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 1995 | 146 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 283 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 147 | 0.040 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 181 | 0.040 |
Why?
|
| Child | 3 | 2015 | 3381 | 0.040 |
Why?
|
| Holistic Health | 1 | 2000 | 13 | 0.040 |
Why?
|
| United States | 2 | 2015 | 5072 | 0.040 |
Why?
|
| Risk Factors | 4 | 2011 | 3942 | 0.040 |
Why?
|
| Pseudobulbar Palsy | 1 | 2000 | 1 | 0.040 |
Why?
|
| Pica | 1 | 2000 | 3 | 0.040 |
Why?
|
| Starvation | 1 | 2000 | 12 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2000 | 14 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 37 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1420 | 0.040 |
Why?
|
| Aged | 4 | 2007 | 7982 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 979 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2013 | 2485 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1997 | 5 | 0.040 |
Why?
|
| Cebus | 1 | 1997 | 4 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1068 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 2803 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 31 | 0.030 |
Why?
|
| HIV | 1 | 1996 | 100 | 0.030 |
Why?
|
| Free Radicals | 1 | 1996 | 72 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 358 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1996 | 74 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1995 | 36 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 38 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2015 | 146 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2015 | 228 | 0.030 |
Why?
|
| Epilepsy | 1 | 2015 | 56 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 90 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 93 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 225 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 48 | 0.030 |
Why?
|
| Hela Cells | 1 | 2015 | 370 | 0.030 |
Why?
|
| Body Composition | 1 | 1995 | 160 | 0.030 |
Why?
|
| Sarcoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Thiobarbiturates | 1 | 1993 | 4 | 0.030 |
Why?
|
| Cacao | 1 | 2013 | 10 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 508 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 358 | 0.030 |
Why?
|
| Carbonated Beverages | 1 | 2013 | 21 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 997 | 0.030 |
Why?
|
| Prospective Studies | 1 | 1997 | 1574 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 27 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2013 | 34 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 256 | 0.030 |
Why?
|
| Coffee | 1 | 2013 | 20 | 0.030 |
Why?
|
| Tea | 1 | 2013 | 46 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2013 | 32 | 0.020 |
Why?
|
| Corn Oil | 1 | 1992 | 1 | 0.020 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1992 | 2 | 0.020 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1992 | 14 | 0.020 |
Why?
|
| Hydroquinones | 1 | 1992 | 10 | 0.020 |
Why?
|
| Food Preservation | 1 | 1992 | 8 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1995 | 253 | 0.020 |
Why?
|
| Carcinoma | 1 | 1994 | 106 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 61 | 0.020 |
Why?
|
| Peroxides | 1 | 1992 | 21 | 0.020 |
Why?
|
| Adenoma | 1 | 1994 | 94 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 358 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 725 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 38 | 0.020 |
Why?
|
| Pregnancy | 1 | 1997 | 1737 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1991 | 98 | 0.020 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 2011 | 3 | 0.020 |
Why?
|
| Endothelium | 1 | 2011 | 28 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 686 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 1991 | 62 | 0.020 |
Why?
|
| Immunity | 1 | 2011 | 60 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 74 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1990 | 27 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 225 | 0.020 |
Why?
|
| Weight Gain | 1 | 1991 | 138 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1990 | 40 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1990 | 66 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 661 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 1998 | 126 | 0.020 |
Why?
|
| Postmenopause | 2 | 1998 | 139 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 115 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 63 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 256 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 95 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 153 | 0.020 |
Why?
|
| Terminal Care | 1 | 2005 | 53 | 0.010 |
Why?
|
| Age Factors | 2 | 1998 | 1139 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 1998 | 1266 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2003 | 36 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2003 | 27 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2003 | 44 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 74 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2003 | 94 | 0.010 |
Why?
|
| HIV Infections | 1 | 1996 | 2535 | 0.010 |
Why?
|
| Menarche | 1 | 1998 | 15 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1998 | 28 | 0.010 |
Why?
|
| Premenopause | 1 | 1998 | 109 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 162 | 0.010 |
Why?
|
| Software | 1 | 1998 | 234 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1998 | 1729 | 0.010 |
Why?
|